The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- HHS “Common Rule” Update Proposes One-Time Consent For Research On Bio-samples; Single IRBs Would Be New Standard Sep. 02, 2015
- Hillary Clinton “Combatting Addiction” Initiative Includes More Access to Naloxone, Medication-Assisted Treatment Sep. 02, 2015
- Accelerated Approval For Biomarkers? FDA Toys With Limited Context of Use Qualification As Effort To Set Standards Begins Aug. 31, 2015
See More Research Notes